新临床状态的多重标准基于价值的定性定价框架"MARIE"
Akina Takami1, Naotaka Sakashita2, Tatsuhiro Uenishi2,3
1Department of Health Policy and Public Health, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
日本的药品定价制度需要基于价值的定价来激励制药创新. 为了估计具有新临床状态的药物的价格,应用了MARIE框架,揭示了显著的价格调整.
科学领域:
- 卫生经济学 卫生经济学
- 制药政策 制药政策
- 药品定价 药品定价 药品定价
背景情况:
- 日本目前的药品定价制度在临床状态变化后调整价格,帮助支出分配.
- 然而,该系统未能将药物价值纳入,从而减少了制药公司在日本开发新药的激励力.
研究的目的:
- 应用基于价值的定价 (VBP) 框架,MARIE,以估计日本新临床状态的药物价格.
- 评估将药物价值纳入新药开发激励措施的定价的影响.
主要方法:
- 使用MARIE框架估计了32种药物在初步批准和新临床状态时的价格.
- 分析了市场扩张率,以估计新适应症患者的最大患者人群.
主要成果:
- 新临床状态的估计价格变化中位数与初始指示相比下降了50.24%.
- 对于初步指示,MARIE估计的价格是初始清单价格的122.12%的中位数.
结论:
- 马里框架为基于价值的药物定价提供了一种实际的多标准方法,特别是对于新的临床状态.
- 根据MARIE的价格调整将基于患者人群类别的变化而发生,反映出不断变化的市场动态.
更多相关视频
08:36The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
Published on: July 28, 2022
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
相关概念视频
Decision Making: P-value Method
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim is also stated. These statements can act as null and alternative hypotheses: a null hypothesis would be a neutral statement while the alternative hypothesis can have a...
Standards of Care I
Standards of Care II
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Clinically Relevant Drug Product Specifications: Methods of Establishment
Bioequivalence of Drugs: Drugs with Multiple Indications
